Brian Heiniger, MD
Ophthalmology · Olathe, KSNPI 1528452463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Glaukos Corporation at 29.9% of the total. 2025 is the largest year on record at $1,352, 2.2 times the $618 reported in 2019.
Across 86 payments — averaging $50.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- Biotissue Holdings Inc.$909
- Alcon$678
- Sun Pharmaceutical Industries Inc.$240
- Sight Sciences, Inc.$190
- Aerie Pharmaceuticals, Inc.$157
- plus $848 from 15 others
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$4,27399%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 12 | $1,290 |
| Biotissue Holdings Inc. | 14 | $909 |
| Alcon | 15 | $678 |
| Sun Pharmaceutical Industries Inc. | 6 | $240 |
| Sight Sciences, Inc. | 2 | $190 |
| Aerie Pharmaceuticals, Inc. | 4 | $157 |
| Ocular Therapeutix, Inc. | 2 | $139 |
| Mallinckrodt Hospital Products Inc. | 5 | $125 |
| Oyster Point Pharma, Inc. | 5 | $90 |
| Rxsight Inc | 4 | $84 |
| Bausch & Lomb Americas Inc. | 3 | $65 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $48 |
| Harrow Eye, LLC | 2 | $48 |
| AbbVie | 2 | $47 |
| Dompe US, Inc. | 2 | $42 |
| NEW World Medical,inc. | 1 | $29 |
| Travere Therapeutics, Inc. | 1 | $24 |
| Lensar, Inc. | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$369
- iStent inject Trabecular Micro-Bypass Stent System$240
- iStent$216
- iStent inject W$216
- OMNI(R) SURGICAL SYSTEM (US)$178
- AcrySof$148
- ORA$143
- AcrySof IQ VIVITY IOL$135
- DEXTENZA$125
- iDoseTR$124
- iStent Infinite$124
- iStent Trabecular Micro-Bypass Stent System$121
- CEQUA$119
- Rhopressa$115
- Rocklatan$115
- Prokera$106
- AmnioGraft$106
- Photrexa$102
How this compares
$4,312 in reported general payments places this provider in the 80th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $54,610 |
| Ketorolac Tromethamine | 825 | $15,019 |
| LumiganBimatoprost | 26 | $12,733 |
| Bromfenac Sodium | 92 | $12,049 |
| Prednisolone Acetate | 486 | $11,451 |
| Cyclosporine | 14 | $10,094 |
| ProlensaBromfenac Sodium | 21 | $7,268 |
| Latanoprost | 333 | $4,051 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $3,014 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 144 | $2,209 |
| Travoprost | 12 | $1,375 |
| Brimonidine Tartrate | 92 | $941 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 44 | $466 |
| Timolol Maleate | 92 | $415 |
| ErythromycinErythromycin Base | 37 | $391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $47 | $67,34283 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $15 | $7,26821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Olathe
- Jeff WongskhaluangOlathe$42K
- Milton GrinOlathe$3K
- Cooper RodgersOlathe$2K
- Daniel DurrieOverland Park$974K
- John DoaneLeawood$496K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Miranda BisharaPrairie Village$45K
- Michael EllisLenexa$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.